

Neuralstem, Inc.  
Form 8-K  
March 17, 2014

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 17, 2014**

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

**Delaware**

**(State or other jurisdiction of  
incorporation or organization)**

**000-1357459**

**(Commission File No.) (IRS Employee Identification No.)**

**52-2007292**

**9700 Great Seneca Highway,**

**Rockville, Maryland 20850**

**(Address of Principal Executive Offices)**

**(301) 366-4841**

**(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On March 17, 2014, Neuralstem, Inc. (“Company”) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) were published in the peer-reviewed journal, “Annals of Neurology” <http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full>. A copy of the press release is attached to this report as Exhibit 99.01.

**Item 9.01 Financial Statement and Exhibits.**

<b>Exhibit Number</b>	<b>Description</b>
99.01	Press Release Dated March 17, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr  
Chief Executive Officer

Dated: March 17, 2014

**INDEX OF EXHIBITS**

**Exhibit Number** Description

99.01 Press Release Dated March 17, 2014